InflaRx N.V. Reports Mid-Year Financial Results
Company Announcements

InflaRx N.V. Reports Mid-Year Financial Results

InflaRx (IFRX) has released an update.

InflaRx N.V., a biopharmaceutical company incorporated in Amsterdam, has released its unaudited condensed consolidated financial statements for the first half of 2024. The report details the company’s financial performance, including revenues, expenses, and comprehensive loss, presented in euros and compared to the previous year’s figures. It reflects the company’s operations, financial position, and cash flows for its subsidiaries located in Germany and the United States.

For further insights into IFRX stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskInflaRx Reports Q3 2024 Financial Results and Progress
TipRanks Auto-Generated NewsdeskInflaRx Reports Rising Revenue Amidst Significant Losses
TheFlyInflaRx reports Q3 EPS (EUR 0.30) vs. (EUR 0.13) last year
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App